# Nicholas C. Turner

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nicholas-c-turner/

## Facts

| Field | Value |
| --- | --- |
| Citations | 46,064 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 92 |
| i10-index | 256 |
| Last Known Institution | Royal Marsden NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5060044961 |
| ORCID iD | https://orcid.org/0000-0001-8937-0873 |
| Works | 1,140 |

## Researcher papers

- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer](https://scholariq.org/papers/mutation-tracking-in-circulating-tumor-dna-predicts-relapse-in-early-breast/)
- [Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review](https://scholariq.org/papers/circulating-tumor-dna-analysis-in-patients-with-cancer-american-society-of/)
- [ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group](https://scholariq.org/papers/esmo-recommendations-on-the-use-of-circulating-tumour-dna-assays-for-patients/)
- [Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer](https://scholariq.org/papers/analysis-of-i-esr1-i-mutation-in-circulating-tumor-dna-demonstrates-evolution/)
- [Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-investigator-choice-chemotherapy-for-metastatic-triple/)
- [Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial](https://scholariq.org/papers/capivasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [Royal Marsden NHS Foundation Trust](https://scholariq.org/institutions/royal-marsden-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.